Omega-3 Prescription Drugs Market Market - Top Companies and Manufacturers

  • Report ID: 6461
  • Published Date: Sep 20, 2024
  • Report Format: PDF, PPT

Companies Dominating the Omega-3 Prescription Drugs Landscape

    The omega-3 prescription drugs market remains fiercely competitive among key players such as Amarin Corporation, Hikma Pharmaceuticals, Nordic Naturals, and DSM. These firms are emphasizing product innovation, strategic collaborations, and further expansion of their global reach. Vascepa by Amarin is among the popular products in the market, especially in cardiovascular health, whereas Hikma and Nordic Naturals continue expanding their product offerings within related markets. For example, In March 2023, Hikma Pharmaceuticals launched Icosapent Ethyl Capsules in the U.S., expanding its omega-3 prescription drugs portfolio. This is indicative of growing consciousness toward the prevention of cardiovascular diseases and exemplifies increasing competition amongst key players in the industry.

    Here are some leading players in the omega-3 prescription drugs market:

    • AstraZeneca plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Amarin Corporation plc
    • Camber Pharmaceuticals, Inc.
    • Dr. Reddy’s Laboratories Ltd.
    • GSK plc
    • Grupo Ferrer Internacional, S.A.
    • Hikma Pharmaceuticals PLC
    • Natco Pharma Limited
    • Pfizer Inc.
    • Viatris Inc.
    • Zydus Lifesciences Limited

Browse Key Market Insights with Data Illustration:

In the News

  • In June 2024, Daewoong Bio introduced a new hyperlipidemia treatment called CRA-TG Soft Capsule. This innovative product combines rosuvastatin, a well-known drug for managing high cholesterol, with omega-3 fatty acids. Omega-3s are commonly used to lower triglyceride levels in patients with high triglycerides.
  • In May 2024, MegaFood launched Omega 3-6-9, which is a plant-based supplement that features a unique blend of fatty acids, including 600 mg of Omega-3, designed to support heart, brain, vision, and joint health. The product is crafted using sustainably sourced Ahiflower and fish-free algae oil to reduce environmental impact.
  • In January 2023, AstraZeneca completed the acquisition of CinCor Pharma, Inc., a biopharmaceutical company specializing in innovative hypertension treatments. This acquisition significantly strengthened AstraZeneca's cardiovascular portfolio and enhanced its research and development capabilities.

Author Credits:  Radhika Pawar


  • Report ID: 6461
  • Published Date: Sep 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The omega-3 prescription drugs market size was USD 1.5 billion in 2024.

The global omega-3 prescription drugs market size was US 1.5 billion in 2024 and is likely to reach USD 4 billion by the end of 2037, expanding at a CAGR of 8% over the forecast period, i.e., 2025-2037.

AstraZeneca plc, Amarin Corporation plc, Camber Pharmaceuticals, Inc., Dr. Reddy’s Laboratories Ltd., GSK plc, Pfizer Inc., Grupo Ferrer Internacional, S.A., Hikma Pharmaceuticals PLC, Natco Pharma Limited, Viatris Inc., Zydus Lifesciences Limited are some key players in the market.

The Vascepa segment is expected to hold a dominating share during the forecast period.

North America is projected to offer lucrative prospects with a share of 45.6% during the forecast period.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample